GPC Biotech Seeks Lung Cancer Drug Partner Before Cash Runs Out
March 25th, 2009
March 25 (Bloomberg) – GPC Biotech AG, the German biotechnology company that agreed to combine with Agennix Inc. last month, aims to find a partner for the experimental talactoferrin cancer drug before cash runs out in 2010.
Talks have begun on a potential licensing deal for the drug, which is in mid-stage human trials for non-small cell lung cancer, Chief Executive Officer Bernd Seizinger said in an interview today.